Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Until we are at 8$

<< Previous

Bullboard Posts

Next >>

Post by Marky1on Feb 20, 2021 10:18am

293 Views

Post# 32618303

Until we are at 8$

I'm off this sight until we are at 8$.....Best of luck to everyone here...We have an excellent product and an excellent team working in our favour.

i just got so angry from Burts accusations, all false of course
I have never lied about anything in the past,present or future
Please don't get shaken out of the tree! 50$ is a very realistic goal
JM

<< Previous

Bullboard Posts

Next >>

Cannara reports record growth and profitability in Q4 2023